The effect of antinuclear antibody titre and its variation on outcomes in children with primary immune thrombocytopenia

Antinuclear antibody (ANA) can be positive in children with primary immune thrombocytopenia (ITP), but the effect of ANA titre and its variation on outcomes of children with primary ITP remains unclear. Here, we conducted a single-centre retrospective cohort study of children with primary ITP at the Peking Union Medical College Hospital in China. A total of 324 children with primary ITP included in this study were followed for a median time of 25 months. In this cohort, 39.2% had an ANA titre of 1:160 or higher. Results from a generalized estimating equation model revealed that patients with higher ANA titres had lower platelet counts at onset but a higher recovery rate of subsequent platelet counts. Results from Cox regression models adjusted for potential confounders revealed that patients with ANA titres of 1:160 or more were more likely to develop to autoimmune disease (AID) than those without, and the risk of AID development increased with the rise of ANA titres (p value for trend less than 0.001). These data highlight the predictive value of ANA titre for platelet counts and the risk of AID development in children with primary ITP.

[1]  Hongmei Song,et al.  Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case–control study in Chinese children , 2022, Annals of Hematology.

[2]  Yiqing Zheng,et al.  High titers of antinuclear antibody and the presence of multiple autoantibodies are highly suggestive of systemic lupus erythematosus , 2022, Scientific Reports.

[3]  D. Vergani,et al.  Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseases , 2022, Journal of translational autoimmunity.

[4]  Bin Wang,et al.  ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases , 2021, Lupus Science & Medicine.

[5]  Shuang Liu,et al.  Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia , 2021, Blood advances.

[6]  H. Al‐Samkari,et al.  Response to rituximab in children and adults with immune thrombocytopenia (ITP) , 2021, Research and practice in thrombosis and haemostasis.

[7]  J. Churpek,et al.  Approach to the diagnosis of aplastic anemia. , 2021, Blood advances.

[8]  B. Bonnotte,et al.  Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments , 2021, HemaSphere.

[9]  S. Holzhauer,et al.  Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP. , 2021, Blood advances.

[10]  E. Sebastián,et al.  Secondary immune thrombocytopenia in children: Characteristics and outcome of a large cohort from two Spanish centres , 2021, Acta paediatrica.

[11]  L. Churilov,et al.  Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease , 2020, Antibodies.

[12]  B. Bonnotte,et al.  Evans’ Syndrome: From Diagnosis to Treatment , 2020, Journal of clinical medicine.

[13]  M. Cicardi,et al.  Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course. , 2020, Clinical and Experimental Immunology.

[14]  W. R. Burack,et al.  FcγRI and FcγRIII on splenic macrophages mediate phagocytosis of anti-glycoprotein IIb/IIIa autoantibody-opsonized platelets in immune thrombocytopenia , 2020, Haematologica.

[15]  K. Ohmura,et al.  2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases , 2020, Modern rheumatology.

[16]  Shuang Liu,et al.  The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia , 2020, Hematology.

[17]  J. Bussel,et al.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia. , 2019, Blood advances.

[18]  D. Gladman,et al.  2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus , 2019, Annals of the rheumatic diseases.

[19]  Sindhu R. Johnson,et al.  The presence of anti-nuclear antibodies alone is associated with changes in B cell activation and T follicular helper cells similar to those in systemic autoimmune rheumatic disease , 2018, Arthritis Research & Therapy.

[20]  Daniel Lüdecke,et al.  ggeffects: Tidy Data Frames of Marginal Effects from Regression Models , 2018, J. Open Source Softw..

[21]  Renhao Li,et al.  Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets. , 2018, Blood.

[22]  L. Abenhaim,et al.  Childhood immune thrombocytopenia: A nationwide cohort study on condition management and outcomes , 2017, Pediatric blood & cancer.

[23]  B. Bonnotte,et al.  Pathogenesis of immune thrombocytopenia. , 2017, Autoimmunity reviews.

[24]  Yong-chun Su,et al.  Clinical Significance of Antinuclear and Antiextractable Nuclear Antigen Antibody in Childhood Immune Thrombocytopenia , 2017, Seminars in Thrombosis and Hemostasis.

[25]  L. Criswell,et al.  2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data‐Driven Methodology Involving Three International Patient Cohorts , 2017, Arthritis & rheumatology.

[26]  María Dueñas,et al.  Simple generalized estimating equations (GEEs) and weighted generalized estimating equations (WGEEs) in longitudinal studies with dropouts: guidelines and implementation in R , 2016, Statistics in medicine.

[27]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[28]  M. Bruin,et al.  Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. , 2014, Blood.

[29]  M. Mayes,et al.  An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative , 2013 .

[30]  Shaoyan Hu,et al.  Correction of abnormal T cell subsets by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. , 2013, Immunology letters.

[31]  Peter Filzmoser,et al.  Exploring incomplete data using visualization techniques , 2012, Adv. Data Anal. Classif..

[32]  Yao-Hsu Yang,et al.  The initial manifestations and final diagnosis of patients with high and low titers of antinuclear antibodies after 6 months of follow-up. , 2011, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[33]  Drew Provan,et al.  International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.

[34]  M. Milhem,et al.  A positive antinuclear antibody test predicts for a poor response to initial steroid therapy in adults with idiopathic thrombocytopenic purpura , 2008, Annals of Hematology.

[35]  O. Ayyıldız,et al.  Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura , 2007, Journal of Thrombosis and Thrombolysis.

[36]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[37]  Søren Højsgaard,et al.  The R Package geepack for Generalized Estimating Equations , 2005 .

[38]  L. Leiva,et al.  Antinuclear Antibody (ANA) and ANA Profile Tests in Children with Autoimmune Disorders: A Retrospective Study , 2000, Clinical Rheumatology.

[39]  M. Sailer,et al.  Usefulness of antinuclear antibody testing to screen for rheumatic diseases , 1997, Archives of disease in childhood.

[40]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .